Comparing psilocybin to metformin as neuroprotective agents against Parkinson's dementia: A systematic review of evidence and efficacy.
Progress in neuro-psychopharmacology & biological psychiatry January 10, 2025 Randall D Ordovich-Clarkson, Maurice Jabbour, Daniel Arteaga Pelayo et al. 7 citations
A systematic review compared metformin and psilocybin as potential prophylactic treatments for Parkinson's disease. Metformin may slow disease progression by reducing oxidative stress and α-synuclein damage in mitochondria. Psilocybin may repair damaged neurons through 5-HT2A receptor activation, increasing brain-derived neurotropic factor and reducing α-synuclein accumulation. The review calls for further research into off-label metformin use and serotonergic compounds for neurodegenerative disease prevention.